• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth to Cease Funding BioSteel Business Unit Furthering Business Transformation and Focus on North American Cannabis Leadership

    9/14/23 8:44:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email

    BioSteel filing immediately eliminates significant cash burn for Canopy Growth and provides for an orderly realization of value of BioSteel's assets through a sale process

    As the senior secured lender to BioSteel, Canopy Growth expects to recover proceeds from the anticipated sale process 

    Management reaffirms its expectation to achieve positive Adjusted EBITDA in all remaining business units exiting FY2024, as the Company focuses on driving growth in its Canadian and U.S. cannabis businesses to position itself as an industry leader in North America

    SMITHS FALLS, ON, Sept. 14, 2023 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced that it has ceased funding BioSteel Sports Nutrition Inc. ("BioSteel") and that BioSteel has commenced proceedings under the Companies' Creditors Arrangement Act (the "CCAA") in the Ontario Superior Court of Justice (Commercial List) ("CCAA Court") and will seek recognition of that proceeding under Chapter 15 of the United States Bankruptcy Code to give full force and effect to the orders made in the CCAA proceeding in the United States, including a stay of proceedings.

    Canopy Growth to Cease Funding BioSteel Business Unit Furthering Business Transformation and Focus on North American Cannabis Leadership (CNW Group/Canopy Growth Corporation)

    As part of its efforts to simplify its business and reduce cash burn, Canopy Growth previously announced that it was reviewing strategic options for the Company's BioSteel business unit, including a potential sale of the business unit. BioSteel's business was a significant drag on Canopy Growth's profitability and cash flow, representing approximately 60% of the Company's Q1 FY2024 Adjusted EBITDA loss. The decision by BioSteel to seek creditor protection means that Canopy Growth will limit the further funding obligations in respect of the BioSteel business unit, which is consistent with Canopy Growth's transformation to a simplified, asset-light operating model and focus on its core cannabis operations. 

    Canopy Growth's financial position is expected to be further strengthened through the immediate removal of the cash expenditures associated with funding the BioSteel business unit and the potential cash proceeds from the orderly sale of BioSteel's assets. Further, the Company anticipates the removal of the previously identified material weakness related to the BioSteel business segment upon disposition. In addition, with BioSteel's operating loss and cash burn eliminated, Canopy Growth reiterates its expectation to achieve positive Adjusted EBITDA across its remaining business units exiting FY2024.

    "Canopy Growth has marked yet another major milestone in our transformation plan, as while BioSteel's business has shown significant year-over-year revenue growth, and we believe the brand remains an attractive asset, it does not align with Canopy Growth's cannabis focused asset-light strategy. We have repeatedly demonstrated that we will take decisive action to enhance our profitability and ensure we are focused and positioned to be a leader in the North American cannabis sector," said David Klein, Chief Executive Officer.

    Recent Transformation Plan Highlights
    • Since July 1, 2023, reduction of the Company's overall debt by approximately CAD $349 million, with further reductions totalling approximately CAD $95 million expected over the next two quarters1.
    • Agreement to sell Hershey Drive facility for CAD $53 million. Upon the completion of the sale, Canopy Growth will have sold a total of seven properties for an aggregate gross amount of approximately CAD $155 million since April 1, 2023.
    • Achieved cost reduction of CAD $47 million in Q1 FY2024, bringing total cost reductions to CAD $172 million since the beginning of FY2023.
    • Management continues to expect restructuring initiatives announced in FY2023 to deliver combined Selling, General & Administrative Expense and Cost of Goods Sold reduction of CAD $240 million to CAD $310 million by the end of FY2024.
    • U.S. THC companies that are expected to be acquired by Canopy USA, LLC ("Canopy USA") continue to demonstrate momentum, strengthening and expanding their businesses and Canopy Growth continues to work with regulators to advance its novel structure.

    BioSteel has obtained an initial order from the CCAA Court which provides for, among other things: (i) a stay of proceedings in favor of BioSteel and its two U.S. affiliates, BioSteel Sports Nutrition USA LLC and BioSteel Manufacturing LLC; and (ii) the appointment of KSV Restructuring Inc. as monitor of BioSteel.

    The CCAA process will allow the BioSteel business to maximize the value of its assets through a court supervised sales process. Canopy Growth remains BioSteel Canada's largest creditor and shareholder and anticipates receiving its proportionate share of any recoveries in the CCAA process.

    _________________________________________

    1 This number assumes that the convertible debentures issued on July 14, 2023 with an aggregate principal amount of approximately $40.4MM are settled by the Company in common shares, which settlement is only possible in the event that shareholders of the Company approve such issuance at a meeting of shareholders on September 25, 2023.

     

    Non-GAAP Measures

    Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted EBITDA is calculated as the reported net income (loss), adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition-related costs. Asset impairments related to periodic changes to the Company's supply chain processes are not excluded from Adjusted EBITDA given their occurrence through the normal course of core operational activities.

    About Canopy Growth

    Canopy Growth is a leading North American cannabis and consumer packaged goods ("CPG") company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to our consumers, Canopy Growth delivers innovative products with a focus on premium and mainstream cannabis brands including Doja, 7ACRES, Tweed, and Deep Space. Canopy Growth's CPG portfolio features targeted 24-hour skincare and wellness solutions from This Works, gourmet wellness products by Martha Stewart CBD, and category defining vaporizer technology made in Germany by Storz & Bickel.

    Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through its rights to Acreage Holdings, Inc., a vertically integrated multi-state cannabis operator with principal operations in densely populated states across the Northeast, as well as Wana Brands, a leading cannabis edible brand in North America, and Jetty Extracts, a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology.

    Beyond our world-class products, Canopy Growth is leading the industry forward through a commitment to social equity, responsible use, and community reinvestment—pioneering a future where cannabis is understood and welcomed for its potential to help achieve greater wellbeing and life enhancement.

    For more information visit www.canopygrowth.com

    References to information included on, or accessible through, our website do not constitute incorporation by reference of the information contained at or available through our website, and you should not consider such information to be part of this press release.

    Notice Regarding Forward Looking Statements

    This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements and uncertainties include statements with respect to BioSteel's intention to complete proceedings under the CCAA; the outcome of the CCAA proceedings and any potential recovery for its stakeholders, including Canopy Growth; the impact on Canopy Growth's financial position, including the potential cash proceeds from the sale of BioSteel's assets; the anticipated removal of the previously identified material weakness related to the BioSteel business segment; expectations regarding the potential success of, and the costs and benefits associated with the Company's transformation plan, including the completion of the Company's sale of its Hershey facility; the assumption that the convertible debentures issued on July 14, 2023 are settled in common shares of the Company; the occurrence and outcome of the Company's restructuring initiatives and Canopy USA's expected acquisition of U.S. THC companies; segment and business focuses for FY2024, including delivering positive Adjusted EBITDA exiting FY2024 and expectations for other economic, business, and/or competitive factors.

    Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including BioSteel's ability to complete any future potential transactions in connection with the CCAA proceedings and the terms and conditions thereof; risks relating to the CCAA process, including uncertainty of any residual value for BioSteel's stakeholders under the CCAA process; negative operating cash flow; uncertainty of additional financing; use of proceeds; volatility in the price of the Company's common shares; inherent uncertainty associated with projections; expectations regarding future investment, growth and expansion of operations; regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial and stock markets and the impacts of increased rates of inflation; legal and regulatory risks inherent in the cannabis industry, including the global regulatory landscape and enforcement related to cannabis; additional dilution; political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation and the interpretation of various laws regulations and policies; public opinion and perception of the cannabis industry; and such other risks contained in the public filings of the Company filed with Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com and with the Securities and Exchange Commission through EDGAR at www.sec.gov/edgar, including under the heading "Risk Factors" in the Company's annual report on Form 10-K for the year ended March 31, 2023 and its subsequently filed quarterly reports on Form 10-Q.

    In respect of the forward-looking statements and information, the Company has provided such statements and information in reliance on certain assumptions that they believe are reasonable at this time. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. Should one or more of the foregoing risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/canopy-growth-to-cease-funding-biosteel-business-unit-furthering-business-transformation-and-focus-on-north-american-cannabis-leadership-301927863.html

    SOURCE Canopy Growth Corporation

    Get the next $CGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    12/22/2021Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Canopy Growth Drives Innovation in High-Demand Segments With Latest Product Launches

      Offerings reflect a focused format strategy in Canada's adult-use market Vapes, high-THC flower, pre-roll joints, and edibles introduced across core brands Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched a series of product innovations targeting Canada's fastest-growing adult-use categories.1 The lineup reflects a focused strategy built around four high-demand formats: vapes, high-THC flower, pre-rolls (including infused), and edibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20

      5/6/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis Brand

      New Brand Features Premium Genetics, Selected for Potency, Terpenes, and Consistency Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched Spectrum Reserve, a new premium medical cannabis brand in Canada. Designed to meet the evolving needs of medical cannabis patients, Spectrum Reserve represents the peak of cannabis cultivation – featuring flower selected for size, potency, and terpene levels through rigorous in-house standards during cultivation and post-harvest. Under this new program, Spectrum Reserve is expected to introduce new strains on a r

      4/2/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Strengthens Balance Sheet with Optional Early Prepayment to Reduce Term Loan by US$100 Million

      Early Prepayment Reduces Annual Interest Expense by US$13 Million, Extends Maturity of Term Loan to September 2027 This news release constitutes a "designated news release" for the purposes of Canopy Growth's prospectus supplement dated June 6, 2024 to its short form base shelf prospectus dated February 28, 2025 Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it has made an optional early prepayment under its senior secured term loan (the "Term Loan") in an aggregate principal amount equal to US$100 million at a discounted price of US

      4/1/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Leadership Updates

    Live Leadership Updates

    See more
    • Canopy USA Announces Appointment of Mr. M. Brooks Jorgensen as President

      A cannabis and beverage alcohol industry executive with more than 25 years of experience, Mr. Jorgensen will lead the unified Canopy USA organization forward with a focus on driving profitable growth across the U.S. With the completed acquisitions of Acreage, Wana, and Jetty, Canopy USA now enters a new chapter of growth across key segments including flower, edibles, vapes, extracts, and through an established retail presence in high potential markets across the Midwest and Northeast BOULDER, Colo., January 6, 2025 /PRNewswire/ - Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. c

      1/6/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Results of Annual General Meeting

      SMITHS FALLS, ON, Sept. 25, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) is pleased to announce today the voting results from its annual general meeting of shareholders held on September 24, 2024 (the "Meeting"). All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated August 1, 2024 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below. Each of the direc

      9/25/24 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Announces Extension of Proxy Voting Deadline for Upcoming Annual General Meeting

      Shareholders now have until September 24, 2024 at 9:00 a.m. (Eastern Time) to submit votes to help ensure a quorum is achieved Your Vote is Important! If you need assistance with voting your shares please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at [email protected] SMITHS FALLS, ON, Sept. 20, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) announced today that it has extended the deadline for the submission of proxies related to its upcoming annual general meeting of shareholders (the "Meeting") to September 24, 2024 at 9:00 a.m. (Eastern time). The Meeting will be held later the same day, at 1:00 p.m.

      9/20/24 4:45:00 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      4/19/24 5:00:49 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      11/3/23 4:30:53 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

      SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

      7/20/23 4:35:52 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canopy Growth upgraded by Bernstein

      Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

      4/4/23 9:09:41 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bernstein initiated coverage on Canopy Growth with a new price target

      Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

      11/2/22 6:11:10 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth upgraded by Canaccord Genuity

      Canaccord Genuity upgraded Canopy Growth from Sell to Hold

      10/26/22 7:36:52 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Financials

    Live finance-specific insights

    See more
    • The Week in Canadian Press Releases: 10 Stories You Need to See

      A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, Feb. 14, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

      2/14/25 6:18:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Reports Third Quarter Fiscal Year 2025 Financial Results

      Strong holiday sales drove Storz & Bickel net revenue growth of 19% year-over-year   Record quarter for Canada medical cannabis with net revenue increasing 16%; international markets cannabis net revenue grew 14% year-over-year    Successfully launched Claybourne infused pre-rolls across Canada, Claybourne rose to #3 market share in the infused pre-roll category in British Columbia and Ontario after 6 weeks in market1 SMITHS FALLS, ON, Feb. 7, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announces its financial results for the third fiscal quarter ended December 31, 2024 ("Q3 FY2025"). All financial information in this press

      2/7/25 7:00:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth to Report Third Quarter Fiscal 2025 Financial Results on February 7, 2025

      SMITHS FALLS, ON, Jan. 24, 2025 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) will release its financial results for the third quarter fiscal year 2025 ended December 31, 2024 before financial markets open on February 7, 2025. Following the release of its third quarter fiscal year 2025 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Judy Hong, CFO on February 7 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://app.webinar.net/yY1K7LrWq9O

      1/24/25 7:30:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    SEC Filings

    See more
    • Canopy Growth Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      4/1/25 7:54:00 AM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canopy Growth Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Canopy Growth Corp (0001737927) (Filer)

      2/28/25 5:19:22 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B5 filed by Canopy Growth Corporation

      424B5 - Canopy Growth Corp (0001737927) (Filer)

      2/28/25 5:17:50 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Yanofsky Theresa sold $1,844 worth of shares (2,004 units at $0.92), decreasing direct ownership by 9% to 20,199 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:17:13 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Lazzarato David Angelo sold $2,764 worth of shares (3,004 units at $0.92), decreasing direct ownership by 12% to 22,886 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:16:37 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Kruh Willy sold $1,851 worth of shares (2,012 units at $0.92), decreasing direct ownership by 18% to 9,272 units (SEC Form 4)

      4 - Canopy Growth Corp (0001737927) (Issuer)

      4/2/25 4:15:15 PM ET
      $CGC
      Medicinal Chemicals and Botanical Products
      Health Care